Trial Profile
A prospective, open label, randomized, active control, parallel design, comparative pharmacokinetics study of Intramuscular Pegaspargase (Hamsyl) of Gennova Biopharmaceuticals Ltd versus Intramuschlar Oncaspar in Pediatric patients with relapsed cased of Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2019
Price :
$35
*
At a glance
- Drugs Pegaspargase (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Gennova Biopharmaceuticals
- 26 Mar 2019 Status changed from not yet recruiting to completed.
- 26 Aug 2016 New trial record